NCT05072015

Systematic Follow up of Second Line Treatments for Parkinson's Disease (Deep Brain Stimulation, Apomorphin Pump, Duodopa Pump)

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 150 (estimated)
• Sponsor: University Hospital, Strasbourg, France · Academic / Other
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

Primary purpose: Fluctuations and dyskinesia evolution in Parkinson's disease patients, one year after initiation of deep brain stimulation, apomorphin pump or duodopa pump Secundary purposes: * Motor complications evolution at 6 months, 2 and 3 years * MDS UPDRS III score at 6 months, 1, 2 and 3 years * non motor complications evolution at 6 months, 1, 2 and 3 years * cognition and psychiatric complications evolution at 6 months, 1, 2 and 3 years * cutaneous and digestive complications at 6 months, 1, 2 and 3 years * neuropathy occurrence at 6 months, 1, 2 and 3 years * medical treatment and Levodopa equivalent dose modifications at 6 months, 1, 2 and 3 years

Conditions

• Parkinson's Disease

Timeline

• Start date: 2022-02-01
• Primary completion: 2022-02-01
• Completion: 2028-03-01
• First posted: 2021-10-08
• Last updated: 2022-02-17

Locations

1 site across 1 country: France